comprehensive -WSS

comprehensive

author：hotspot 2025-08-19 18:07:06 - browse：542

Illustration of a laptop on top of a TV with a hand sticking out, holding a newspaper. -- coverage from STAT — Adobe

WASHINGTON – If you live in this city, you’re probably awash in pharmacy benefit manager ads — whether you’re listening to an NPR podcast, reading the New York Times, streaming “Yellowstone,” or watching the U.S. Open Golf Championships. It doesn’t matter if it’s 5 a.m., primetime, or 11 p.m.; in between ads for dog joint supplements and the “Barbie” movie, you will inevitably learn about these middlemen of the prescription drug market.

Ads eviscerating and glorifying PBMs have been around for years. But they’ve intensified over the past three months as Congress scrutinizes PBMs’ role in shaping high drug prices. Over a half-dozen U.S. House and Senate Committees have started investigating PBMs, advancing bipartisan legislation to increase transparency in the industry; ban PBMs from charging more for a drug than what they pay (and pocketing the difference); and require them to pass all fees, rebates, and other payments they receive to insurers.

Lobbying groups have responded to this legislative push with dueling campaigns in the court of public opinion. On one side is the Pharmaceutical Care Management Association, the trade association representing PBMs, which argues that pharmaceutical companies are responsible for high drug prices. On the other side is the industry group PhRMA, which points the finger right back, saying that PBMs are really to blame. Both trade associations have launched ad campaigns worth millions of dollars, blanketing TV, radio, social media, print, and beyond.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： CVS is on a mission to consolidate health care. Will it work?

leisure time

WSS

TikTok, Instagram influencers need more rules for drug ads

Prior authorization reform is both possible and imperative

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

Printout prescription drug information shouldn’t go digital

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Head of FDA's diagnostics center, who led through Covid, retires

focus

comprehensive

knowledge

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Sanders wants to replace patents with prizes for drug inventions

Heart attack and stroke risk calculators need revising

A woman pleads guilty to fire that kept a Wyoming abortion clinic from opening for a year

How to save PrEP access — and even expand it

The inclusion problem at the heart of rehabilitation research

Anesthesiologist group: stop taking Ozempic before surgery

Mystery swirls around US soldier who entered North Korea days ago, officials say

Cancer drug shortages should be causing more outrage

Hormonal contraceptives don’t actually treat endometriosis

Wikipedia

There's an unseen cost to disruptive road

Stanford president’s abrupt resignation sparks debate

Printout prescription drug information shouldn’t go digital

A pediatrician calls for Congress to pass the child tax credit deal

'CMA Fest' 2023: How to watch, who is performing and more

The stock market has soared this year, but will it last? Experts weigh in

leisure time

hotspot

entertainment

hotspot